Navigation Links
Breast tenderness in women getting combo hormone therapy associated with increase in breast density
Date:10/14/2011

Post-menopausal women who experience new onset breast tenderness after starting combination hormone therapy may have an increased risk of breast cancer compared to women who don't experience breast tenderness, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has shown. One reason for this may be that their breasts are becoming more dense.

The new onset tenderness was much more pronounced after initiation of estrogen and progestin therapy than in women getting estrogen therapy alone. The association between new onset breast tenderness and changes in breast density also was more pronounced in the women getting the combination hormone therapy, said study first author Dr. Carolyn Crandall, a professor of general internal medicine and a scientist with UCLA's Jonsson Comprehensive Cancer Center.

Multiple population studies have shown that higher breast density is associated with a higher risk of breast cancer. In women with extremely dense breasts, the cancer risk can be four to six times higher than for women whose breasts are not dense, Crandall said.

Although the present study design did not permit Crandall to directly test whether combined hormone therapyinduced breast tenderness represents increased breast cell proliferation, mammographic density is felt to be an indirect measure of breast tissue growth.

The study appears this week in the early online edition of the peer-reviewed journal Breast Cancer Research and Treatment.

For this prospective study, Crandall and her team examined the association between new onset breast tenderness and change in mammographic density after initiation of hormone therapy in 695 women enrolled in the Women's Health Initiative (WHI). Launched in 1991, the WHI consisted of a set of clinical trials and an observational study involving161,808 generally healthy, postmenopausal women.

Crandall looked at women on the combination therapy as well as women taking only estrogen. They analyzed the development of breast tenderness - the absence of baseline breast tenderness and the presence of tenderness at year one follow-up. They also examined change from baseline density in mammograms, measuring the percent of tissue that was dense, and density percentages from year one and two of the WHI.

"New breast tenderness that begins after a woman initiates therapy with routine doses of estrogen is common and almost double that of women taking a placebo," Crandall said. "It's even higher in women who also are taking a progestin, about three times higher than women given placebos."

Among women assigned to the combination therapy, mean increase in mammographic density was greater among participants reporting new onset of breast tenderness (11.3 percent at year 1) than among participants without new onset breast tenderness (3.9 percent at year one). However, in women who took estrogen alone, breast density was not any different between those who experienced new onset breast tenderness and those who did not, Crandall said.

This is important, Crandall said, because estrogens can increase the risk of uterine cancer and often are paired with progestin to prevent the malignancy in those who have not had a hysterectomy. So while the combination protects women from uterine cancer, it is increasing their risk of developing a breast cancer.

"These findings parallel what is known about breast cancer risk from the WHI. Breast cancer risk was elevated by combination estrogen and progestin therapy, but not by estrogen alone," Crandall said. "Now we know that new onset breast tenderness after combination therapy, but not estrogen alone, is associated with greater increases in breast density."

Using the WHI data, Crandall's team had previously shown in 2009 that women who experienced new onset breast tenderness after initiating combination hormone therapy had a 48% higher risk of subsequent breast cancer than women who did not experience new onset breast tenderness.

These new findings shed light on the biology that might partly explain the link between new onset breast tenderness and increased breast cancer risk during combination therapy, Crandall said. Understanding factors associated with mammographic density changes during therapy with estrogen and progestin may help give biological insights into hormone therapy-associated breast cancer risk.

"These findings emphasize the complexity inherent in the use of surrogate risk markers to assess menopausal hormone therapy-associated breast cancer risk," the study concludes.


'/>"/>
Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles Health Sciences
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest ... centric payment system, to expand its focus on patient care by providing an ... , “At Ogden Clinic, we are working to become a different type ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider of circulating ... in circulating tumor cells using microfluidic western blotting” in Nature Communications on March ... technology to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... providing insurance assistance, financial planning, and related services to residents of the region, ... promote awareness of threatened species and wild lands. , Endangered Species International is ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that ... bypasses that. Healthcare facilities across the country are always forced to focus ... and hospitals, across the country, an efficient and quick way to estimate savings ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... that its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 23, 2017 ReportsnReports.com adds Global ... research report. The global vagus nerve stimulation market analyst ... focus toward minimally invasive VNS procedures. Few years ago, ... developed countries having high standards of healthcare infrastructure. ... ...
(Date:3/22/2017)... LONDON , March 22, 2017 /PRNewswire/ ... Insight Outlook 2022" report gives comprehensive insight ... growth of global biosimilar insulin market. This ... of insulin molecule, mechanism of insulin in ... of biosimilar insulins along with market overview, ...
(Date:3/22/2017)... , March 22, 2017  ImaginAb Inc. today announced the ... Joseph Limber , chairman of ImaginAb, said "At ... track record that is directly relevant to our business, particularly in ... believe that with his leadership, we can realize our potential." ... Mr. Coombs is a ...
Breaking Medicine Technology: